Antifungal drug response in an in vitro model of dermatophyte nail infection

Medical Mycology

Volumn 42, Issue 2, 2004, Pages 159-163

  Osborne, Colin S ^a,b   Leitner, I ^a   Favre, B ^c   Ryder, N S ^a,b  

^a NOVARTIS RESEARCH INSTITUTE   (Austria)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Antifungals; Onychomycosis; Trichophyton rubrum

Indexed keywords

AMOROLFINE; ANTIFUNGAL AGENT; CICLOPIROXOLAMINE; CLOTRIMAZOLE; FLUCONAZOLE; FUNGICIDE; GRISEOFULVIN; ITRACONAZOLE; NAFTIFINE; TERBINAFINE;

ARTICLE; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DERMATOPHYTE; DRUG RESPONSE; FUNGICIDAL ACTIVITY; FUNGUS CULTURE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; MINIMUM INHIBITORY CONCENTRATION; MYCELIUM; ONYCHOMYCOSIS; TRICHOPHYTON RUBRUM;

ANTIFUNGAL AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; NAPHTHALENES; ONYCHOMYCOSIS; TRICHOPHYTON;

FUNGI; TRICHOPHYTON; TRICHOPHYTON RUBRUM;

EID: 1842863494     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/13693780310001656803     Document Type: Article

References (36)

1. Heikkila H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol 1995; 133: 699-703.
2. Sigurgeirsson B, Steingrimsson O, Sveinsdottir S. Prevalence of onychomycosis in Iceland: a population-based study. Acta Derm Venereol 2002; 82: 467-469.
3. Ghannoum MA, Hajjeh RA, Scher R, Konnikov N, Gupta AK, Summerbell R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2000; 43: 641-648.
4. Gupta AK, Konnikov N, Lynde CW, Summerbell RC, Albreski D, Baran R, et al. Onychomycosis: predisposed populations and some predictors of suboptimal response to oral antifungal agents. Eur J Dermatol 1999; 9: 633-638.
5. Evans EG. Causative pathogens in onychomycosis and the possibility of treatment resistance: a review. J Am Acad Dermatol 1998; 38(5 Pt 3): S32-S36.
6. Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev 1995; 8: 240-259.
7. Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1992; 126(S39): 2-7.
8. Jessup CJ, Ryder NS, Ghannoum MA. An evaluation of the in vitro activity of terbinafine. Med Mycol 2000; 38: 155-159.
9. Fernandez-Torres B, Vazquez-Veiga H, Llovo X, Pereiro M Jr, Guarro J. In vitro susceptibility to itraconazole, clotrimazole, ketoconazole and terbinafine of 100 isolates of Trichophyton rubrum. Chemotherapy 2000; 46: 390-394.
10. Fernandez-Torres B, Carrillo AJ, Martin E, Del Palacio A, Moore MK, Valverde A, et al. In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob Ag Chemother 2001; 45: 2524-2528.
11. Perea S, Fothergill AW, Sutton DA, Rinaldi MG. Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method. J Clin Microbiol 2001; 39: 385-388.
12. Arzeni D, Barchiesi F, Compagnucci P, Cellini A, Simonetti O, Offidani AM, et al. In vitro activity of terbinafine against clinical isolates of dermatophytes. Medical Mycology 1998; 36: 235-237.
13. Hofbauer B, Leitner I, Ryder NS. In vitro susceptibility of Microsporum canis and other dermatophyte isolates from veterinary infections during therapy with terbinafine or griseofulvin. Med Mycol 2002; 40: 179-183.
14. Petranyi G, Meingassner JG, Mieth H. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrob Ag Chemother 1987; 31: 1365-1368.
15. Nimura K, Niwano Y, Ishiduka S, Fukumoto R. Comparison of in vitro antifungal activities of topical antimycotics launched in 1990s in Japan. Int J Antimicrobl Agents 2001; 18: 173-178.
16. Hazen KC. Fungicidal versus fungistatic activity of terbinafine and itraconazole: an in vitro comparison. J Am Acad Dermatol 1998; 38(5 Pt 3): S37-S41.
17. Gupta AK, Ahmad I, Summerbell RC. Comparative efficacies of commonly used disinfectants and antifungal pharmaceutical spray preparations against dermatophytic fungi. Med Mycol 2001; 39: 321-328.
18. Fukuda T, Naka W, Tajima S, Nishikawa T. Neutral red assay in minimum fungicidal concentrations of antifungal agents. J Med Vet Mycol 1996; 34: 353-356.
19. Clayton YM. Relevance of broad-spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses. Br J Dermatol 1994; 130(S43): 7-8.
20. Faergemann J, Zehender H, Denouel J, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Derm Venereol 1993; 73: 305-309.
21. Faergemann J, Zehender H, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol 1994; 19: 121-126.
22. Evans EG, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. Br Med J 1999; 318: 1031-1035.
23. Heikkila H, Stubb S. Long-term results in patients with onychomycosis treated with terbinafine or itraconazole. Br J Dermatol 2002; 146: 250-253.
24. Cribier BJ, Paul C. Long-term efficacy of antifungals in toenail onychomycosis: a critical review. Br J Dermatol 2001; 145: 446-452.
25. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Approved standard M38-A. Wayne, PA: NCCLS, 2000.
26. Favre B, Hofbauer B, Hildering KS, Ryder NS. Comparison of in vitro activities of 17 antifungal drugs against a panel of 20 dermatophytes by using a microdilution assay. J Clin Microbiol 2003; 41: 4817-4819.
27. Takasuka T. Amino acid- or protein-dependent growth of Trichophyton mentagrophytes and Trichophyton rubrum. FEMS Immunol Med Mic 2000; 29: 241-245.
28. Rashid A, Scott EM, Richardson MD. Inhibitory effect of terbinafine on the invasion of nails by Trichophyton mentagrophytes. J Am Acad Dermatol 1995; 33(5 Pt 1): 718 -723.
29. Rashid A, Scott E, Richardson MD. Early events in the invasion of the human nail plate by Trichophyton mentagrophytes. Br J Dermatol 1995; 133: 932-940.
30. Richardson MD. Effect of Lamisil and azole antifungals in experimental nail infection. Dermatology 1997; 194(S1): 27-31.
31. Okeke CN, Tsuboi R, Kawai M, Ogawa H. Fluorometric assessment of in vitro antidermatophytic activities of antimycotics based on their keratin-penetrating power. J Clin Microbiol 2000; 38: 489-491.
32. Oycka CA, Gugnani HC. Keratin degradation by Scytalidium species and Fusarium solani. Mycoses 1997; 41: 73-76.
33. Jessup CJ, Warner J, Isham N, Hasan I, Ghannoum MA. Antifungal susceptibility testing of dermatophytes: establishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates. J Clin Microbiol 2000; 38: 341-344.
34. Seebacher C. Limits of brief treatment of onychomycoses. Hautarzt 1998; 49: 705-708.
35. Arrese JE, Pierard-Franchimont C, Pierard GE. A plea to bridge the gap between antifungals and the management of onychomycosis. Am J Clin Dermatol 2001; 2: 281-284.
36. Mukherjee PK, Leidich SD, Isham N, Leitner I, Ryder NS, Ghannoum MA. Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine. Antimicrob Ag Chemother 2003; 47: 82-86.